Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials.

Celine YehMengxi ZhouNeil BapodraDawn HershmanEdward EspinalMarina MoranMaria RiveroAntonio Tito FojoSusan E Bates

Published in: Breast cancer research and treatment (2023)

Values of g, estimated using data collected while a patient is enrolled in a clinical trial is an excellent biomarker of OS. Our results correlate with the survival outcomes of PALOMA-3 and argue strongly for using g as a clinical trial endpoint to help inform go/no-go decisions, improve trial efficiency, and deliver novel therapies to patients sooner.

Keyphrases

clinical trial
phase ii
phase iii
study protocol
end stage renal disease
open label
electronic health record
double blind
ejection fraction
chronic kidney disease
newly diagnosed
big data
prognostic factors
peritoneal dialysis
machine learning
data analysis